<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02937454</url>
  </required_header>
  <id_info>
    <org_study_id>FER-CARS-06</org_study_id>
    <secondary_id>2016-001467-36</secondary_id>
    <nct_id>NCT02937454</nct_id>
  </id_info>
  <brief_title>Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency</brief_title>
  <acronym>Affirm-AHF</acronym>
  <official_title>A Randomised, Double-Blind Placebo Controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalisations and Mortality in Iron Deficient Patients Admitted for Acute Heart Failure (Affirm-AHF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vifor (International) Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Worldwide Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cytel Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vifor Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and&#xD;
      Iron Deficiency (Affirm-AHF)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised, double-blind, placebo-controlled Trial (RCT). The 52 weeks observation&#xD;
      period following randomisation is considered appropriate to investigate the primary endpoint&#xD;
      of recurrent HF hospitalisations and CV death. To evaluate the effect of intravenous ferric&#xD;
      carboxymaltose (IV FCM) in iron deficient subjects with AHF, subjects will be enrolled during&#xD;
      a hospital stay (Index hospitalisation) after the acute care treatment of the index event has&#xD;
      been stabilised. All subjects will continue to receive their established standard therapy for&#xD;
      HF and medical emergencies will be treated according to local routine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 3, 2017</start_date>
  <completion_date type="Actual">July 21, 2020</completion_date>
  <primary_completion_date type="Actual">July 21, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HF Hospitalizations and CV Death</measure>
    <time_frame>up to 52 weeks after randomization</time_frame>
    <description>HF = Heart Failure, CV = Cardiovascular.&#xD;
The composite of recurrent HF hospitalizations and CV death up to 52 weeks after randomization&#xD;
Total hospitalisations included first and recurrent events. If a participant was hospitalised for heart failure and died within 24 h from any cardiovascular event, this was counted as one event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrent CV Hospitalisations and CV Death</measure>
    <time_frame>up to 52 weeks after randomization</time_frame>
    <description>CV = Cardiovascular&#xD;
The composite of recurrent CV hospitalisations and CV death at 52 weeks after randomisation&#xD;
Total hospitalisations included first and recurrent events. If a participant was hospitalised for a cardiovascular reason and died within 24 h of admission from any cardiovascular event, this was counted as one event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HF Hospitalisations</measure>
    <time_frame>up to 52 weeks after randomisation</time_frame>
    <description>HF = Heart Failure&#xD;
HF hospitalisations up to 52 weeks after randomisation analysed as recurrent event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CV Mortality</measure>
    <time_frame>at 52 weeks after randomisation.</time_frame>
    <description>CV = Cardiovascular&#xD;
CV mortality analysed as time to first event at 52 weeks after randomisation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of HF Hospitalisations or CV Death</measure>
    <time_frame>at 52 weeks after randomisation</time_frame>
    <description>HF = Heart Failure, CV = Cardiovascular&#xD;
Analysed as time to first event at 52 weeks after randomisation. The number of participants with at least one HF Hospitalisation or CV Death is presented below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days Lost Due to HF Hospitalisation or CV Death</measure>
    <time_frame>at 52 weeks after randomisation</time_frame>
    <description>HF = Heart Failure, CV = Cardiovascular&#xD;
Number of days lost due to heart failure hospitalisations or cardiovascular death corresponds to the total number of days in hospital for heart failure from randomisation to last known date. Days lost due to cardiovascular death are added to the number of days lost due to heart failure hospitalisation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>HF Hospitalisations</measure>
    <time_frame>up to 52 weeks after randomisation</time_frame>
    <description>HF = Heart Failure&#xD;
Number of participants with at least one HF Hospitalisation up to 52 weeks after randomisation</description>
  </other_outcome>
  <other_outcome>
    <measure>CV Hospitalisations</measure>
    <time_frame>up to 52 weeks after randomisation</time_frame>
    <description>CV = Cardiovascular&#xD;
Number of participants with at least one CV Hospitalisation up to 52 weeks after randomisation</description>
  </other_outcome>
  <other_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>up to 52 weeks after randomisation</time_frame>
    <description>Number of participants who died up to 52 weeks after randomisation</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in NYHA Functional Class</measure>
    <time_frame>at 6, 12, 24 and 52 weeks after randomisation</time_frame>
    <description>NYHA = New York Heart Association&#xD;
NYHA functional class was assessed as Class I, II, III, IV or V:&#xD;
Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc.&#xD;
Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.&#xD;
Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m). Comfortable only at rest.&#xD;
Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients. If a participant was hospitalised at any point during any post-baseline visit and did not have any NYHA assessment for this visit, then Class IV was to be imputed for the visit.&#xD;
Class V - Imputed for participants who died.&#xD;
Lower response categories are better for score NYHA.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in the EQ-5D-5L Questionnaire Indexed Value</measure>
    <time_frame>at 6, 24 and 52 weeks after randomisation</time_frame>
    <description>EQ-5D-5L: European Quality of Life-5 Dimensions-5 Levels&#xD;
The EQ 5D questionnaire consists of a health descriptive system for participants to self-classify and rate their health status on the day of administration.&#xD;
The descriptive system includes 5 items/dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, which are coded from 1 (best state) to 5 (worst state).</description>
  </other_outcome>
  <other_outcome>
    <measure>KCCQ-12 Repeated-Measures Model for Analysis of Treatment Difference</measure>
    <time_frame>up to 52 weeks after randomisation</time_frame>
    <description>KCCQ = Kansas City Cardiomyopathy Questionnaire&#xD;
The KCCQ 12 is a health-related quality of life questionnaire for Heart Failure. It is a 12 item questionnaire that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge and Quality of life. Scores are generated for each domain and scaled from 0 to 100, with 0 denoting the lowest reportable health status and 100 the highest reportable health status.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1132</enrollment>
  <condition>Iron Deficiency</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>ferric carboxymaltose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The first dose of study treatment will be administered for all randomised subjects while the patient is still hospitalised for the Index hospitalisation. The subsequent administrations of study treatment will be done as part of the outpatient clinic visits.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal saline 0.9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The first dose of study treatment will be administered for all randomised subjects on the same day as randomisation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ferric carboxymaltose</intervention_name>
    <description>FCM will be administered as an undiluted bolus injection. The study treatment dose (mL) to be administered will be determined by the patient's body weight and haemoglobin (Hb) value at the respective visits where study treatment will be administered</description>
    <arm_group_label>ferric carboxymaltose</arm_group_label>
    <other_name>Injectafer</other_name>
    <other_name>Ferinject</other_name>
    <other_name>Renegy</other_name>
    <other_name>Iroprem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal saline 0.9%</intervention_name>
    <description>Normal saline will be administered as a bolus injection.</description>
    <arm_group_label>normal saline 0.9%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Currently hospitalised for an episode of acute heart failure (AHF) where AHF was the&#xD;
             primary reason for hospitalisation. All of the following (i.e., items a to d) must&#xD;
             apply:&#xD;
&#xD;
               1. Upon admission for the AHF episode, persistent dyspnoea at rest in a recumbent&#xD;
                  sitting position (30-45°) or with minimal exertion&#xD;
&#xD;
               2. Upon or during the AHF admission, at least 2 of the following clinical findings&#xD;
                  were present: i. Congestion on chest X-ray ii. Rales on chest auscultation iii.&#xD;
                  Oedema ≥1+ on a 0-3+ scale, indicating indentation of skin with mild digital&#xD;
                  pressure that requires 10 or more seconds to resolve in any dependent area&#xD;
                  including extremities or sacral region iv. Elevated jugular venous pressure (≥8&#xD;
                  cm H2O)&#xD;
&#xD;
               3. Natriuretic peptide levels, measured ≤72 hours of the AHF admission must have&#xD;
                  been: i. Brain natriuretic peptide (BNP) ≥400 pg/mL or N-terminal-pro-brain&#xD;
                  natriuretic peptide (NT-proBNP) ≥1,600 pg/mL or ii. BNP ≥600 pg/mL or NT-proBNP&#xD;
                  ≥2,400 pg/mL for subjects presenting with atrial fibrillation when the blood&#xD;
                  sample was taken iii. For subjects treated with an angiotensin receptor&#xD;
                  neprilysin inhibitor (ARNI) in the previous 4 weeks prior to randomisation only&#xD;
                  NT-proBNP values should be considered&#xD;
&#xD;
               4. AHF episode treated with minimally 40 mg of IV furosemide (or equivalent IV loop&#xD;
                  diuretic defined as 20 mg of torasemide or 1 mg of bumetanide)&#xD;
&#xD;
          2. Subject is iron deficient defined as serum ferritin &lt;100 ng/mL or 100 ng/mL ≤ serum&#xD;
             ferritin ≤299 ng/mL if TSAT &lt;20%.&#xD;
&#xD;
          3. Left ventricular ejection fraction &lt;50% (assessed and documented within 12 months&#xD;
             prior to randomisation).&#xD;
&#xD;
          4. Male or female aged ≥18 years old.&#xD;
&#xD;
          5. Subject (or legally acceptable representative)* has provided the appropriate written&#xD;
             informed consent. Subject must provide written informed consent before any&#xD;
             study-specific procedures are performed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Dyspnoea due to non-cardiac causes such as acute or chronic respiratory disorders or&#xD;
             infections (i.e., severe chronic obstructive pulmonary disease, acute bronchitis,&#xD;
             pneumonia, primary pulmonary hypertension).&#xD;
&#xD;
          2. Temperature &gt;38°C (oral or equivalent), active infective endocarditis, sepsis,&#xD;
             systemic inflammatory response syndrome, or any other active infection requiring&#xD;
             anti-microbial treatment at any time during an Index hospitalisation. (Note that it&#xD;
             does NOT include short-term prophylactic administration of antibiotics or short-term&#xD;
             temperature elevation at admission which is no longer present at the time point of&#xD;
             discharge/randomisation).&#xD;
&#xD;
          3. Documented restricted amyloid myocardiopathy, or acute myocarditis or hypertrophic&#xD;
             obstructive, restrictive, or constrictive cardiomyopathy. (Note that it does NOT&#xD;
             include restrictive mitral filling patterns seen on Doppler echocardiographic&#xD;
             assessments of diastolic function).&#xD;
&#xD;
          4. Clinical evidence of acute coronary syndrome, transient ischemic attack or stroke,&#xD;
             within the last 30 days prior randomisation.&#xD;
&#xD;
          5. Severe valvular or left ventricular outflow obstruction disease needing intervention.&#xD;
&#xD;
          6. Coronary-artery bypass graft, cardiac resynchronisation therapy device implantation,&#xD;
             percutaneous intervention (e.g., cardiac, cerebrovascular, aortic, diagnostic&#xD;
             catheters are allowed) or major surgery that led to significant blood loss, including&#xD;
             thoracic and cardiac surgery, within the last 3 months prior to randomisation.&#xD;
&#xD;
          7. Subject has a body weight &lt;35 kg at randomisation.&#xD;
&#xD;
          8. Subject at an immediate need of transfusion or with a Hb &lt;8 g/dL* or with a Hb &gt;15&#xD;
             g/dL.&#xD;
&#xD;
          9. Subjects on treatment for Vitamin B12 and/or serum folate deficiency. Note: Use of&#xD;
             Vitamin B12 and folic acid as supplement therapy (not for deficiency treatment) is&#xD;
             permitted.&#xD;
&#xD;
         10. Subject with a known anaemia not attributed to ID (e.g., other microcytic anaemia) or&#xD;
             with an evidence of iron overload (e.g., haemochromatosis) or disturbances in the&#xD;
             utilisation of iron.&#xD;
&#xD;
         11. Subject has known hypersensitivity to any of the study products to be administered or&#xD;
             known serious hypersensitivity to other parenteral iron products.&#xD;
&#xD;
         12. Subject with known severe allergies including drug allergies, history of severe&#xD;
             asthma, eczema or other atopic allergy and in subjects with immune or inflammatory&#xD;
             conditions (e.g., systemic lupus erythematosus, rheumatoid arthritis).&#xD;
&#xD;
         13. History of erythropoietin stimulating agent, IV iron therapy, and/or blood transfusion&#xD;
             in previous 3 months prior to randomisation.&#xD;
&#xD;
         14. Oral iron therapy at doses &gt;100 mg/day in previous 4 weeks prior to randomisation.&#xD;
             Note: Ongoing use of multivitamins containing iron &lt;75 mg/day are permitted.&#xD;
&#xD;
         15. Currently receiving systemic chemotherapy and/or radiotherapy.&#xD;
&#xD;
         16. Renal dialysis (previous, current or planned within the next 6 months).&#xD;
&#xD;
         17. Subject has known active malignancy of any organ system, i.e., clinical evidence of&#xD;
             current malignancy or not in stable remission for at least 3 years since completion of&#xD;
             last treatment with exception of non-invasive basal cell carcinoma, squamous cell&#xD;
             carcinoma of the skin or cervical intra-epithelial neoplasia.&#xD;
&#xD;
         18. Terminal illness other than HF with expected survival &lt;12 months.&#xD;
&#xD;
         19. Chronic liver disease (including active hepatitis) and/or alanine transaminase or&#xD;
             aspartate transaminase above 3 times the upper limit of the normal range.&#xD;
&#xD;
         20. Subjects with known hepatitis B surface antigen positivity and/or hepatitis C virus&#xD;
             ribonucleic acid positivity.&#xD;
&#xD;
         21. Subject previously randomised into this study. Note: Subjects may be rescreened but&#xD;
             when rescreened, all tests must fall inside the maximum specified screening windows&#xD;
             for each criterion.&#xD;
&#xD;
         22. Subject is currently enrolled in or has completed any other investigational device or&#xD;
             drug study &lt;30 days prior to screening, or is receiving other investigational&#xD;
             agent(s).&#xD;
&#xD;
         23. Subject is pregnant (e.g., positive human chorionic gonadotropin test) or breast&#xD;
             feeding.&#xD;
&#xD;
         24. If of childbearing potential, subject is not using adequate contraceptive precautions.&#xD;
             Subject must agree to use adequate contraception during the study and for 1 month&#xD;
             after the last dose of study treatment. A highly effective method of birth control&#xD;
             must be used.&#xD;
&#xD;
         25. Subject has a history of drug or alcohol abuse within 2 years prior to screening.&#xD;
&#xD;
         26. Subject has a significant medical condition(s), anticipated need for major surgery&#xD;
             during the study, or any other kind of disorder that may be associated with increased&#xD;
             risk to the subject, or may interfere with study assessments, outcomes, or the ability&#xD;
             to provide written informed consent or comply with study procedures, in the&#xD;
             Investigator's opinion.&#xD;
&#xD;
               -  Following section in italics is applicable for The Netherlands, Spain and&#xD;
                  Singapore only (NL, ES and SG only): 'The lower threshold of Hb values is set to&#xD;
                  10 g/dL.'&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piotr Ponikowski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Clinical Military Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Austral</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InCor -Instituto do Coração HCFMUSP</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Rijeka</name>
      <address>
        <city>Rijeka</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aleksandre Aladashvili Clinic LLC</name>
      <address>
        <city>Tbilisi</city>
        <zip>0102</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Baruch Pade Medical Center</name>
      <address>
        <city>Tiberias</city>
        <state>Lower Galilee</state>
        <zip>15208</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Kerem University Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civilia di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American University of Beirut Medical Center</name>
      <address>
        <city>Beirut</city>
        <zip>1107-2020</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vasculair Onderzoek Centrum</name>
      <address>
        <city>Hoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Military Hospital</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-891</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency Clinical Hospital</name>
      <address>
        <city>Bucharest</city>
        <zip>014461</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Heart Centre of Singapore Pte</name>
      <address>
        <city>Singapore</city>
        <zip>169609</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Murcia</name>
      <address>
        <city>Murcia</city>
        <zip>30001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Malmö</city>
        <zip>SE 20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The M.D. Strazhesko Institute of Cardiology</name>
      <address>
        <city>Kyiv</city>
        <zip>02000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital NHS Foundation</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Croatia</country>
    <country>Georgia</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Lebanon</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 14, 2016</study_first_submitted>
  <study_first_submitted_qc>October 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2016</study_first_posted>
  <results_first_submitted>April 23, 2021</results_first_submitted>
  <results_first_submitted_qc>May 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 18, 2021</results_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Heart Failure</keyword>
  <keyword>Iron Deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT02937454/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 26, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT02937454/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FCM (Ferric Carboxymaltose)</title>
          <description>Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates.</description>
        </group>
        <group group_id="P2">
          <title>Placebo (Normal Saline (NaCl 0.9%))</title>
          <description>Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="567"/>
                <participants group_id="P2" count="565"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Treatment</title>
              <participants_list>
                <participants group_id="P1" count="559"/>
                <participants group_id="P2" count="551"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="427"/>
                <participants group_id="P2" count="437"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="128"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FCM (Ferric Carboxymaltose)</title>
          <description>Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates.</description>
        </group>
        <group group_id="B2">
          <title>Placebo (Normal Saline (NaCl 0.9%))</title>
          <description>Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="559"/>
            <count group_id="B2" value="551"/>
            <count group_id="B3" value="1110"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 65 and 84 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="369"/>
                    <measurement group_id="B2" value="370"/>
                    <measurement group_id="B3" value="739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 85 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="244"/>
                    <measurement group_id="B2" value="250"/>
                    <measurement group_id="B3" value="494"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="315"/>
                    <measurement group_id="B2" value="301"/>
                    <measurement group_id="B3" value="616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="498"/>
                    <measurement group_id="B2" value="489"/>
                    <measurement group_id="B3" value="987"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Croatia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Georgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lebanon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HF Hospitalizations and CV Death</title>
        <description>HF = Heart Failure, CV = Cardiovascular.&#xD;
The composite of recurrent HF hospitalizations and CV death up to 52 weeks after randomization&#xD;
Total hospitalisations included first and recurrent events. If a participant was hospitalised for heart failure and died within 24 h from any cardiovascular event, this was counted as one event.</description>
        <time_frame>up to 52 weeks after randomization</time_frame>
        <population>Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.&#xD;
The management and follow-up of patients was affected by the COVID-19 pandemic. Participants were censored in each country on the date when the first patient with COVID-19 was reported in the respective country.</population>
        <group_list>
          <group group_id="O1">
            <title>FCM (Ferric Carboxymaltose)</title>
            <description>Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline (NaCl 0.9%))</title>
            <description>Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates.</description>
          </group>
        </group_list>
        <measure>
          <title>HF Hospitalizations and CV Death</title>
          <description>HF = Heart Failure, CV = Cardiovascular.&#xD;
The composite of recurrent HF hospitalizations and CV death up to 52 weeks after randomization&#xD;
Total hospitalisations included first and recurrent events. If a participant was hospitalised for heart failure and died within 24 h from any cardiovascular event, this was counted as one event.</description>
          <population>Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.&#xD;
The management and follow-up of patients was affected by the COVID-19 pandemic. Participants were censored in each country on the date when the first patient with COVID-19 was reported in the respective country.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="558"/>
                <count group_id="O2" value="550"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Full Analysis Set (FAS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293"/>
                    <measurement group_id="O2" value="372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Covid-19 Sensitivity Analysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274"/>
                    <measurement group_id="O2" value="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Full Analysis Set (FAS)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.059</p_value>
            <method>Negative binomial model</method>
            <method_desc>Negative binomial model adjusted for baseline covariates: sex, age, HF aetiology, HF duration, and country.</method_desc>
            <param_type>Annualised event rate ratio (RR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Covid-19 Sensitivity Analysis</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.024</p_value>
            <method>Negative binomial model</method>
            <method_desc>Negative binomial model adjusted for baseline covariates: sex, age, HF aetiology, HF duration, and country.</method_desc>
            <param_type>Annualised event rate ratio (RR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrent CV Hospitalisations and CV Death</title>
        <description>CV = Cardiovascular&#xD;
The composite of recurrent CV hospitalisations and CV death at 52 weeks after randomisation&#xD;
Total hospitalisations included first and recurrent events. If a participant was hospitalised for a cardiovascular reason and died within 24 h of admission from any cardiovascular event, this was counted as one event.</description>
        <time_frame>up to 52 weeks after randomization</time_frame>
        <population>Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.&#xD;
The management and follow-up of patients was affected by the COVID-19 pandemic. Participants were censored in each country on the date when the first patient with COVID-19 was reported in the respective country.</population>
        <group_list>
          <group group_id="O1">
            <title>FCM (Ferric Carboxymaltose)</title>
            <description>Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline (NaCl 0.9%))</title>
            <description>Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates.</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrent CV Hospitalisations and CV Death</title>
          <description>CV = Cardiovascular&#xD;
The composite of recurrent CV hospitalisations and CV death at 52 weeks after randomisation&#xD;
Total hospitalisations included first and recurrent events. If a participant was hospitalised for a cardiovascular reason and died within 24 h of admission from any cardiovascular event, this was counted as one event.</description>
          <population>Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.&#xD;
The management and follow-up of patients was affected by the COVID-19 pandemic. Participants were censored in each country on the date when the first patient with COVID-19 was reported in the respective country.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="558"/>
                <count group_id="O2" value="550"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Full Analysis Set (FAS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="370"/>
                    <measurement group_id="O2" value="451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COVID-19 sensitivity analyses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="350"/>
                    <measurement group_id="O2" value="440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Full Analysis Set (FAS)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.050</p_value>
            <method>Negative binomial model</method>
            <method_desc>Negative binomial model adjusted for baseline covariates: sex, age, HF aetiology, HF duration, and country.</method_desc>
            <param_type>Annualised event rate ratio (RR)</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>COVID-19 sensitivity analyses</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.024</p_value>
            <method>Negative binomial model</method>
            <method_desc>Negative binomial model adjusted for baseline covariates: sex, age, HF aetiology, HF duration, and country.</method_desc>
            <param_type>Annualised event rate ratio (RR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HF Hospitalisations</title>
        <description>HF = Heart Failure&#xD;
HF hospitalisations up to 52 weeks after randomisation analysed as recurrent event.</description>
        <time_frame>up to 52 weeks after randomisation</time_frame>
        <population>Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.&#xD;
The management and follow-up of patients was affected by the COVID-19 pandemic. Participants were censored in each country on the date when the first patient with COVID-19 was reported in the respective country.</population>
        <group_list>
          <group group_id="O1">
            <title>FCM (Ferric Carboxymaltose)</title>
            <description>Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline (NaCl 0.9%))</title>
            <description>Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates.</description>
          </group>
        </group_list>
        <measure>
          <title>HF Hospitalisations</title>
          <description>HF = Heart Failure&#xD;
HF hospitalisations up to 52 weeks after randomisation analysed as recurrent event.</description>
          <population>Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.&#xD;
The management and follow-up of patients was affected by the COVID-19 pandemic. Participants were censored in each country on the date when the first patient with COVID-19 was reported in the respective country.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="558"/>
                <count group_id="O2" value="550"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Full Analysis Set (FAS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                    <measurement group_id="O2" value="294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COVID-19 sensitivity analyses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202"/>
                    <measurement group_id="O2" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Full Analysis Set (FAS)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>Negative binomial model</method>
            <method_desc>Negative binomial model adjusted for baseline covariates: sex, age, HF aetiology, HF duration, and country.</method_desc>
            <param_type>Annualised event rate ratio (RR)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>COVID-19 sensitivity analyses</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Negative binomial model</method>
            <method_desc>Negative binomial model adjusted for baseline covariates: sex, age, HF aetiology, HF duration, and country.</method_desc>
            <param_type>Annualised event rate ratio (RR)</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CV Mortality</title>
        <description>CV = Cardiovascular&#xD;
CV mortality analysed as time to first event at 52 weeks after randomisation.</description>
        <time_frame>at 52 weeks after randomisation.</time_frame>
        <population>Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.&#xD;
The management and follow-up of patients was affected by the COVID-19 pandemic. Participants were censored in each country on the date when the first patient with COVID-19 was reported in the respective country.</population>
        <group_list>
          <group group_id="O1">
            <title>FCM (Ferric Carboxymaltose)</title>
            <description>Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline (NaCl 0.9%))</title>
            <description>Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates.</description>
          </group>
        </group_list>
        <measure>
          <title>CV Mortality</title>
          <description>CV = Cardiovascular&#xD;
CV mortality analysed as time to first event at 52 weeks after randomisation.</description>
          <population>Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.&#xD;
The management and follow-up of patients was affected by the COVID-19 pandemic. Participants were censored in each country on the date when the first patient with COVID-19 was reported in the respective country.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="558"/>
                <count group_id="O2" value="550"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Full Analysis Set (FAS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COVID-19 sensitivity analyses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Full Analysis Set (FAS)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.809</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression adjusted for sex, age, HF aetiology, HF duration, and country at baseline.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Covid-19 Sensitivity Analysis</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.687</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression adjusted for sex, age, HF aetiology, HF duration, and country at baseline</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite of HF Hospitalisations or CV Death</title>
        <description>HF = Heart Failure, CV = Cardiovascular&#xD;
Analysed as time to first event at 52 weeks after randomisation. The number of participants with at least one HF Hospitalisation or CV Death is presented below.</description>
        <time_frame>at 52 weeks after randomisation</time_frame>
        <population>Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.&#xD;
The management and follow-up of patients was affected by the COVID-19 pandemic. Participants were censored in each country on the date when the first patient with COVID-19 was reported in the respective country.</population>
        <group_list>
          <group group_id="O1">
            <title>FCM (Ferric Carboxymaltose)</title>
            <description>Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline (NaCl 0.9%))</title>
            <description>Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of HF Hospitalisations or CV Death</title>
          <description>HF = Heart Failure, CV = Cardiovascular&#xD;
Analysed as time to first event at 52 weeks after randomisation. The number of participants with at least one HF Hospitalisation or CV Death is presented below.</description>
          <population>Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.&#xD;
The management and follow-up of patients was affected by the COVID-19 pandemic. Participants were censored in each country on the date when the first patient with COVID-19 was reported in the respective country.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="558"/>
                <count group_id="O2" value="550"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Full Analysis Set (FAS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181"/>
                    <measurement group_id="O2" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COVID-19 sensitivity analyses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175"/>
                    <measurement group_id="O2" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Full Analysis Set (FAS)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression adjusted for sex, age, HF aetiology, HF duration, and country at baseline</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Covid-19 Sensitivity Analysis</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression adjusted for sex, age, HF aetiology, HF duration, and country at baseline</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days Lost Due to HF Hospitalisation or CV Death</title>
        <description>HF = Heart Failure, CV = Cardiovascular&#xD;
Number of days lost due to heart failure hospitalisations or cardiovascular death corresponds to the total number of days in hospital for heart failure from randomisation to last known date. Days lost due to cardiovascular death are added to the number of days lost due to heart failure hospitalisation.</description>
        <time_frame>at 52 weeks after randomisation</time_frame>
        <population>Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.&#xD;
The management and follow-up of patients was affected by the COVID-19 pandemic. Participants were censored in each country on the date when the first patient with COVID-19 was reported in the respective country.</population>
        <group_list>
          <group group_id="O1">
            <title>FCM (Ferric Carboxymaltose)</title>
            <description>Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline (NaCl 0.9%))</title>
            <description>Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates.</description>
          </group>
        </group_list>
        <measure>
          <title>Days Lost Due to HF Hospitalisation or CV Death</title>
          <description>HF = Heart Failure, CV = Cardiovascular&#xD;
Number of days lost due to heart failure hospitalisations or cardiovascular death corresponds to the total number of days in hospital for heart failure from randomisation to last known date. Days lost due to cardiovascular death are added to the number of days lost due to heart failure hospitalisation.</description>
          <population>Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.&#xD;
The management and follow-up of patients was affected by the COVID-19 pandemic. Participants were censored in each country on the date when the first patient with COVID-19 was reported in the respective country.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="558"/>
                <count group_id="O2" value="550"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Full Analysis Set (FAS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="9.06"/>
                    <measurement group_id="O2" value="6.2" spread="14.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COVID-19 sensitivity analyses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="8.18"/>
                    <measurement group_id="O2" value="6.1" spread="14.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Full Analysis Set (FAS)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.035</p_value>
            <method>Negative binomial model</method>
            <method_desc>Negative binomial model adjusted for baseline covariates: sex, age, HF aetiology, HF duration, and country.</method_desc>
            <param_type>Annualised event rate ratio (RR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Covid-19 Sensitivity Analysis</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Negative binomial model</method>
            <method_desc>Negative binomial model adjusted for baseline covariates: sex, age, HF aetiology, HF duration, and country</method_desc>
            <param_type>Annualised event rate ratio (RR)</param_type>
            <param_value>0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>HF Hospitalisations</title>
        <description>HF = Heart Failure&#xD;
Number of participants with at least one HF Hospitalisation up to 52 weeks after randomisation</description>
        <time_frame>up to 52 weeks after randomisation</time_frame>
        <population>Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.</population>
        <group_list>
          <group group_id="O1">
            <title>FCM (Ferric Carboxymaltose)</title>
            <description>Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline (NaCl 0.9%))</title>
            <description>Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates.</description>
          </group>
        </group_list>
        <measure>
          <title>HF Hospitalisations</title>
          <description>HF = Heart Failure&#xD;
Number of participants with at least one HF Hospitalisation up to 52 weeks after randomisation</description>
          <population>Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="558"/>
                <count group_id="O2" value="550"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Full Analysis Set (FAS)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression adjusted for sex, age, HF aetiology, HF duration, and country at baseline.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>CV Hospitalisations</title>
        <description>CV = Cardiovascular&#xD;
Number of participants with at least one CV Hospitalisation up to 52 weeks after randomisation</description>
        <time_frame>up to 52 weeks after randomisation</time_frame>
        <population>Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.</population>
        <group_list>
          <group group_id="O1">
            <title>FCM (Ferric Carboxymaltose)</title>
            <description>Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline (NaCl 0.9%))</title>
            <description>Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates.</description>
          </group>
        </group_list>
        <measure>
          <title>CV Hospitalisations</title>
          <description>CV = Cardiovascular&#xD;
Number of participants with at least one CV Hospitalisation up to 52 weeks after randomisation</description>
          <population>Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="558"/>
                <count group_id="O2" value="550"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181"/>
                    <measurement group_id="O2" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Full Analysis Set (FAS)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression adjusted for sex, age, HF aetiology, HF duration, and country at baseline.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>All-cause Mortality</title>
        <description>Number of participants who died up to 52 weeks after randomisation</description>
        <time_frame>up to 52 weeks after randomisation</time_frame>
        <population>Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.</population>
        <group_list>
          <group group_id="O1">
            <title>FCM (Ferric Carboxymaltose)</title>
            <description>Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline (NaCl 0.9%))</title>
            <description>Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates.</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Mortality</title>
          <description>Number of participants who died up to 52 weeks after randomisation</description>
          <population>Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="558"/>
                <count group_id="O2" value="550"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Full Analysis Set (FAS)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.944</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression adjusted for sex, age, HF aetiology, HF duration, and country at baseline</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in NYHA Functional Class</title>
        <description>NYHA = New York Heart Association&#xD;
NYHA functional class was assessed as Class I, II, III, IV or V:&#xD;
Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc.&#xD;
Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.&#xD;
Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m). Comfortable only at rest.&#xD;
Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients. If a participant was hospitalised at any point during any post-baseline visit and did not have any NYHA assessment for this visit, then Class IV was to be imputed for the visit.&#xD;
Class V - Imputed for participants who died.&#xD;
Lower response categories are better for score NYHA.</description>
        <time_frame>at 6, 12, 24 and 52 weeks after randomisation</time_frame>
        <population>Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.</population>
        <group_list>
          <group group_id="O1">
            <title>FCM (Ferric Carboxymaltose)</title>
            <description>Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline (NaCl 0.9%))</title>
            <description>Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in NYHA Functional Class</title>
          <description>NYHA = New York Heart Association&#xD;
NYHA functional class was assessed as Class I, II, III, IV or V:&#xD;
Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc.&#xD;
Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.&#xD;
Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m). Comfortable only at rest.&#xD;
Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients. If a participant was hospitalised at any point during any post-baseline visit and did not have any NYHA assessment for this visit, then Class IV was to be imputed for the visit.&#xD;
Class V - Imputed for participants who died.&#xD;
Lower response categories are better for score NYHA.</description>
          <population>Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="558"/>
                <count group_id="O2" value="550"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="557"/>
                    <count group_id="O2" value="547"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Class I</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class II</title>
                  <measurement_list>
                    <measurement group_id="O1" value="255"/>
                    <measurement group_id="O2" value="240"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class III</title>
                  <measurement_list>
                    <measurement group_id="O1" value="272"/>
                    <measurement group_id="O2" value="277"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class IV</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class V</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="516"/>
                    <count group_id="O2" value="514"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Class I</title>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class II</title>
                  <measurement_list>
                    <measurement group_id="O1" value="296"/>
                    <measurement group_id="O2" value="271"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class III</title>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="151"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class IV</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class V</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="488"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Class I</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class II</title>
                  <measurement_list>
                    <measurement group_id="O1" value="296"/>
                    <measurement group_id="O2" value="267"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class III</title>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="131"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class IV</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class V</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="495"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Class I</title>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class II</title>
                  <measurement_list>
                    <measurement group_id="O1" value="288"/>
                    <measurement group_id="O2" value="265"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class III</title>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class IV</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class V</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="449"/>
                    <count group_id="O2" value="463"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Class I</title>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class II</title>
                  <measurement_list>
                    <measurement group_id="O1" value="234"/>
                    <measurement group_id="O2" value="223"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class III</title>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class IV</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class V</title>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Full Analysis Set (FAS)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.196</p_value>
            <method>Generalised Estimating Equations (GEE)</method>
            <method_desc>The following variables are included in the GEE model: treatment, visit, baseline NYHA class, sex, age, HF aetiology, HF duration, and country</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in the EQ-5D-5L Questionnaire Indexed Value</title>
        <description>EQ-5D-5L: European Quality of Life-5 Dimensions-5 Levels&#xD;
The EQ 5D questionnaire consists of a health descriptive system for participants to self-classify and rate their health status on the day of administration.&#xD;
The descriptive system includes 5 items/dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, which are coded from 1 (best state) to 5 (worst state).</description>
        <time_frame>at 6, 24 and 52 weeks after randomisation</time_frame>
        <population>Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.</population>
        <group_list>
          <group group_id="O1">
            <title>FCM (Ferric Carboxymaltose)</title>
            <description>Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline (NaCl 0.9%))</title>
            <description>Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the EQ-5D-5L Questionnaire Indexed Value</title>
          <description>EQ-5D-5L: European Quality of Life-5 Dimensions-5 Levels&#xD;
The EQ 5D questionnaire consists of a health descriptive system for participants to self-classify and rate their health status on the day of administration.&#xD;
The descriptive system includes 5 items/dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, which are coded from 1 (best state) to 5 (worst state).</description>
          <population>Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.</population>
          <units>Change from baseline in EQ-5D-5L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="558"/>
                <count group_id="O2" value="550"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="476"/>
                    <count group_id="O2" value="465"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.01"/>
                    <measurement group_id="O2" value="0.03" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="422"/>
                    <count group_id="O2" value="410"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.01"/>
                    <measurement group_id="O2" value="0.05" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="365"/>
                    <count group_id="O2" value="363"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.01"/>
                    <measurement group_id="O2" value="0.06" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.208</p_value>
            <method>Mixed-effect model of repeated measures</method>
            <method_desc>MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment*Visit + Baseline covariates.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.408</p_value>
            <method>Mixed-effect model of repeated measures</method>
            <method_desc>MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment*Visit + Baseline covariates.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.999</p_value>
            <method>Mixed-effect model of repeated measures</method>
            <method_desc>MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment*Visit + Baseline covariates.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>KCCQ-12 Repeated-Measures Model for Analysis of Treatment Difference</title>
        <description>KCCQ = Kansas City Cardiomyopathy Questionnaire&#xD;
The KCCQ 12 is a health-related quality of life questionnaire for Heart Failure. It is a 12 item questionnaire that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge and Quality of life. Scores are generated for each domain and scaled from 0 to 100, with 0 denoting the lowest reportable health status and 100 the highest reportable health status.</description>
        <time_frame>up to 52 weeks after randomisation</time_frame>
        <population>Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.</population>
        <group_list>
          <group group_id="O1">
            <title>FCM (Ferric Carboxymaltose)</title>
            <description>Ferric carboxymaltose (FCM), administered by bolus intravenous (IV) injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the participant's body weight and haemoglobin (Hb) level.&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24), depending on the participant's Hb levels measured prior to planned dosing dates.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Normal Saline (NaCl 0.9%))</title>
            <description>Normal saline (NaCl 0.9%), administered by bolus intravenous (IV) injection at a volume corresponding to the FCM dose determined by the participant's body weight and haemoglobin (Hb) level (i.e., 10 ml or 20 ml per administration).&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the participant's Hb levels measured prior to planned dosing dates.</description>
          </group>
        </group_list>
        <measure>
          <title>KCCQ-12 Repeated-Measures Model for Analysis of Treatment Difference</title>
          <description>KCCQ = Kansas City Cardiomyopathy Questionnaire&#xD;
The KCCQ 12 is a health-related quality of life questionnaire for Heart Failure. It is a 12 item questionnaire that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge and Quality of life. Scores are generated for each domain and scaled from 0 to 100, with 0 denoting the lowest reportable health status and 100 the highest reportable health status.</description>
          <population>Full Analysis Set (FAS): All randomised participants for whom administration of study treatment was started and who had at least one post-baseline visit (including calls), death or hospitalisation or who withdrew from the study after but not on the randomisation date.</population>
          <units>KCCQ-12 score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="558"/>
                <count group_id="O2" value="550"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="490"/>
                    <count group_id="O2" value="484"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.53" spread="1.16"/>
                    <measurement group_id="O2" value="17.24" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="476"/>
                    <count group_id="O2" value="480"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.26" spread="1.18"/>
                    <measurement group_id="O2" value="18.36" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="475"/>
                    <count group_id="O2" value="461"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.49" spread="1.20"/>
                    <measurement group_id="O2" value="19.88" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="439"/>
                    <count group_id="O2" value="451"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.57" spread="1.24"/>
                    <measurement group_id="O2" value="21.88" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="422"/>
                    <count group_id="O2" value="413"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.30" spread="1.26"/>
                    <measurement group_id="O2" value="23.32" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="386"/>
                    <count group_id="O2" value="379"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.78" spread="1.28"/>
                    <measurement group_id="O2" value="23.70" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="368"/>
                    <count group_id="O2" value="370"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.75" spread="1.33"/>
                    <measurement group_id="O2" value="24.31" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.227</p_value>
            <method>Mixed-effect model of repeated measures</method>
            <method_desc>MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment*Visit + Baseline covariates.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>Mixed-effect model of repeated measures</method>
            <method_desc>MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment*Visit + Baseline covariates.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Mixed-effect model of repeated measures</method>
            <method_desc>MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment*Visit + Baseline covariates.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Mixed-effect model of repeated measures</method>
            <method_desc>MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment*Visit + Baseline covariates.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.028</p_value>
            <method>Mixed-effect model of repeated measures</method>
            <method_desc>MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment*Visit + Baseline covariates.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 36</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.136</p_value>
            <method>Mixed-effect model of repeated measures</method>
            <method_desc>MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment*Visit + Baseline covariates.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.329</p_value>
            <method>Mixed-effect model of repeated measures</method>
            <method_desc>MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment*Visit + Baseline covariates.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During treatment period up to 52 weeks after randomization</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1 - FCM (Ferric Carboxymaltose)</title>
          <description>Ferric carboxymaltose (FCM), administered by bolus IV injection at a dose of 10 ml or 20 ml of undiluted solution (containing 500 mg or 1,000 mg of iron respectively) depending on the subject's body weight and Hb level.&#xD;
From a single dose given at Visit 2 (Week 0) up to 4 doses given over 24 weeks (at Visit 2 (Week 0), Visit 3 (Week 6), Visit 4 (Week 12) and Visit 5 (Week 24)), depending on the subject's Hb levels measured prior to planned dosing dates.</description>
        </group>
        <group group_id="E2">
          <title>Group 2 - Placebo (Normal Saline (NaCl 0.9%))</title>
          <description>Normal saline (NaCl 0.9%), administered by bolus IV injection at a volume corresponding to the FCM dose determined by the subject's body weight and Hb level (i.e., 10 ml or 20 ml per administration).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="250" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="282" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="559"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy mediastinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="163" subjects_affected="116" subjects_at_risk="559"/>
                <counts group_id="E2" events="215" subjects_affected="127" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="559"/>
                <counts group_id="E2" events="23" subjects_affected="17" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="32" subjects_affected="20" subjects_at_risk="559"/>
                <counts group_id="E2" events="35" subjects_affected="23" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="559"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="559"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="559"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="559"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="559"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="559"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Aortic valve disease mixed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Cardiac amyloidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Cardiorenal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Nodal arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Ventricular dyssynchrony</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Corneal decompensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Large intestinal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Presbyoesophagus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Intestinal infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="559"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="559"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="559"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Heart transplant rejection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="559"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="559"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="559"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="559"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="559"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Osteomyelitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Suspected COVID-19</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Shewanella algae bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Pharyngeal injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Postoperative thoracic procedure complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Traumatic haemothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Heart rate abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>International normalised ratio decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Hyperglycaemic hyperosmolar nonketotic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Fracture nonunion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Sarcopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="559"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Thrombotic cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion incomplete</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="559"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="559"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>End stage renal disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Urinary tract inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="559"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="559"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Dyspnoea at rest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Orthopnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Diabetic vascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Varicose ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="551"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="57" subjects_affected="51" subjects_at_risk="559"/>
                <counts group_id="E2" events="49" subjects_affected="45" subjects_at_risk="551"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>FER-CARS-06 Clinical Study Team</name_or_title>
      <organization>Vifor (International) AG.</organization>
      <phone>+41 588 518 000</phone>
      <email>FER-CARS-06.study@viforpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

